Newsletter: February 2023
MAPS published our first email newsletter in 2003, and since then a lot has changed! The psychedelic community has grown exponentially, psychedelic research is being conducted by many groups around the …
Newsletters
Newsletter: January 2023
Prior Positive Results Confirmed in MAPS-Sponsored, Philanthropy-Funded Phase 3 January 26, 2023 In monumental psychedelic news, on January 5, we confirmed prior positive results in our philanthropy-funded …
Newsletter: December 2022
Database Locked and Finalized for Phase 3 Trial of MDMA-Assisted Therapy for PTSD (MAPP2) December 21, 2022 Together, we have been on a 36-year journey to obtain FDA approval for the therapeutic use of …
Newsletter: November 2022
Second MAPS-Sponsored Phase 3 Trial of MDMA-Assisted Therapy for PTSD Completed November 22, 2022 For two decades, MAPS’ donors have supported our sponsorship of clinical trials, and we’re delighted …
Newsletter: October 2022
Final Call for Submissions: Frontiers in Psychiatry Special Edition October 21, 2022 We are accepting submissions for papers to be included in MDMA-Assisted Therapy for Treatment of PTSD and Beyond, a …
Newsletter: September 2022
Following Landmark Achievement, California Psychedelic Decriminalization Bill Slated for 2023 Reintroduction September 22, 2022 On September 1, after California Senate Bill 519 (SB 519) was reduced to …
Newsletter: August 2022
MAPS, in Coordination with Allies, Assists U.S. Sentencing Commission in Reaching Quorum August 24, 2022 The middle of August brought an exciting milestone for MAPS! On August 17, we celebrated the appointment …
Newsletter: July 2022
New Digital Learning Course: Psychedelic Fundamentals July 27, 2022 This month has brought exciting forward momentum in the world of psychedelic research and education! Before we explore the latest news, …
Newsletter: June 2022
Support Psychedelic Therapy During PTSD Awareness Month Netflix releases trailer for How To Change Your Mind series June 23, 2022 Every day, but especially during PTSD Awareness Month, we are reminded …
Newsletter: May 2022
MAPS Completes Enrollment for Phase 3 Trial of MDMA-Assisted Therapy for PTSD May 26, 2022 We have exciting news! On May 9, the interim analysis of MAPS’ second Phase 3 trial of MDMA-assisted therapy …
Newsletter: April 2022
Revised Edition of The Secret Chief Revealed: Conversations with Leo Zeff, Pioneer in the Underground Psychedelic Therapy Movement Now Available April 21, 2022 One of the most important texts in the history …
Newsletter: March 2022
Michael Mullette Joins MAPS PBC Senior Leadership as Chief Operating Officer March 29, 2022 On March 8, MAPS Public Benefit Corporation (MAPS PBC) announced that Michael Mullette, an experienced drug development …